글로벌 콜드 글루티닌 질환 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

최근 몇 년 동안, 냉응집소 질환 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. 냉응집소 질환(CAD)은 클론 B 세포 림프증식 세포(AIHA)에 영향을 미치는 드문 자가면역성 용혈성 빈혈 하위 집합입니다 . CAD는 AIHA의 15-25%에서 발생하며 주로 중년 및 노인에게 영향을 미칩니다. 골수 유래 클론 B 림프구가 동결 온도(0-4°C)에 노출되면 적혈구에 부착하여 응집을 일으키고 결국 면역 매개 용혈을 일으키는 자가항체를 생성합니다.

Data Bridge Market Research는 2021년 저온 응집소 질환 시장이 7,200만 달러 규모였으며 2029년까지 2억 9,346만 달러에 도달할 것으로 예상하고 2022년에서 2029년까지의 예측 기간 동안 19.20%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

한랭응집소병은 신체의 면역 체계가 추운 기온에 노출되어 적혈구를 공격하고 파괴하는 희귀한 유형의 후천성 자가면역성 용혈성 빈혈입니다. 추운 기온이나 바이러스 감염은 한랭응집소병(CAD)의 증상을 유발하거나 악화시킬 수 있으며, 이 질환을 앓고 있는 대부분의 사람들은 피로, 손과 발이 차가움, 현기증, 두통, 창백한 피부, 짙은 소변, 황달, 흉통, 허리 통증, 다리 통증, 설사, 심장 문제 및 구토와 같은 용혈성 빈혈 증상을 경험합니다.

보고 범위 및 시장 세분화

저온응집소질환 시장 동향

운전자

• 저온응집소병 유병률 증가

저온 응집소 질환의 유병률 증가는 시장 성장을 촉진할 것으로 추정됩니다. 특정 유형의 암, 박테리아 감염, 기생충 감염, 바이러스성 질환 및 기타 자가면역 질환은 2차 저온 응집소 질환의 유병률을 초래하는 위험 요인입니다.

• 의료 인프라에 대한 투자 증가

저온 응집소 질환 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 인프라를 개선하는 데 도움이 되는 의료비 지출 증가입니다. 또한 다양한 정부 기관은 자금을 늘려 의료 인프라를 개선하려고 하며 이는 시장 역학에 더욱 영향을 미칠 것입니다.

• 노령 인구의 증가

급증하는 노령 인구는 2022-2029년 예측 기간 동안 시장 확장을 강화할 것으로 추산됩니다. 세계보건기구(WHO)에 따르면 2010년에 5억 2,400만 명이 넘을 것으로 추산되었던 전 세계 노령 인구는 2050년까지 거의 20억 명으로 증가할 것으로 예상됩니다. 노령 인구는 면역 체계가 약화되어 냉응집소병에 걸릴 가능성이 더 높으며, 이는 시장 성장률을 더욱 높일 것으로 추산됩니다.

또한, 공공 및 민간 기관에서 인식을 확산하기 위한 이니셔티브가 증가함에 따라 냉응집증 시장이 확대될 것입니다. 또한, 사람들의 가처분 소득 수준과 앉아서 지내는 생활 방식의 증가로 냉응집증 시장이 확대될 것입니다.

기회

• 연구개발 활동의 증가       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the cold agglutinin disease market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the cold agglutinin disease market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the cold agglutinin disease market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This cold agglutinin disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cold agglutinin disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

People between the ages of 40 and 80 are most likely to get cold agglutinin disease (CAD). The median age for symptom start is roughly 65 years old, which means that half of those affected develop symptoms before this age and the other half after. The disease affects roughly 16 individuals per million (prevalence), and one person per million develops the disease each year (incidence). In comparison to men, women are nearly twice as likely to develop the condition.

Cold agglutinin disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cold Agglutinin Disease Market

Over the projected period, the cold agglutinin disease market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the cold agglutinin disease market.

Recent Development

• In February 2022, the U.S. Food and Drug Administration (FDA) had approved Enjaymo (sutimlimab-jome) with the objective of reducing the need for red blood cell transfusion due to haemolysis in adults with cold agglutinin disease (CAD). It is the first as well as only approved treatment for people suffering from CAD. This medication functions by inhibiting the destruction of red blood cells (haemolysis).

Global Cold Agglutinin Disease Market Scope

The cold agglutinin disease market is segmented on the basis of drugs, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Corticosteroids
• Alkylating Agents
• Purine Nucleoside Analogs
• Biologics
• Others

Dosage form

• Tablets
• Injections
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cold Agglutinin Disease Market Regional Analysis/Insights

The cold agglutinin disease market is analysed and market size insights and trends are provided by country, drugs, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the cold agglutinin disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the cold agglutinin disease market because of the rise in adoption of newer technologies in this region. Additionally, rising healthcare expenditure and surging demand for disease specific treatment will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to increasing patient pool in this region. Also, the development of healthcare infrastructure and rising geriatric population will further propel themarket's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Cold Agglutinin Disease Market Share Analysis

The cold agglutinin disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cold agglutinin disease market.

Some of the major players operating in the cold agglutinin disease market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• AstraZeneca (UK)
• Johnson & Johnson (US)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Apellis Pharmaceuticals (US)
• Incyte Corporation (US)
• Fresenius Kabi AG (Germany)
• Amgen Inc. (US)
• Bristol-Myers Squibb Company (US)
• AbbVie Inc. (US)
• Eli Lilly and Company (US)
• Merck KGaA (Germany)

SKU-54102